Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD
Study to assess ability of GAL-101 eye drops in slowing or stopping the growth of geographic atrophy, a severe form of age-related macular degeneration Trial planned to enroll 110 patients in the US, Europe, and Israel Study design discussed with FDA and …